Thursday, September 30, 2004

MURRYSVILLE, Pa. - Domestic sales of Respironics’ sleep therapy products jumped in the fourth quarter by 28% over the same quarter last year. Overall, revenues increased by 16% to $206 million for the company’s fourth quarter, and to $760 million for the fiscal year that ended June 30. That compares to $630 million in sales for previous year. Most of the company’s growth was organic since its acquisition of Novametrix and Fuji RC were completed in 2002.
ELYRIA, Ohio - Invacare’s sales for the second quarter ending June 30 increased by 13% to $339 million over the same quarter last year. Acquisitions accounted for roughly half the percentage point gain and foreign currency translation accounted for another three points. Invacare’s respiratory products sales increased 16%, largely due to strong sales of the Homefill II. Although standard products sales were up in terms of volume, lower pricing pulled down overall revenues by 1%. Rehab sales were up by 19%.
CHATSWORTH, Calif. - Thanks to higher sales of its electronic and pneumatic conservers, CHAD Therapeutics turned in its best quarterly revenue performance in seven years. CHAD reported that the company is gaining share in the domestic conserver market and that international sales have jumped 16%. Sales of the company’s transfilling oxygen system, the Total O2, met expectations for the first quarter, but the company can’t yet say whether the system will become a significant contributor to CHAD’S growth. HME